Widely used:Recently Viewed
Clear All
$261 Mln
--
1.79
--
0
-32.07 %
--
--
--
-357273
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Compass Therapeutics Inc (CMPX)
| 23.72 | 27.81 | 135.37 | 1.05 | -18.07 | -- | -- |
|
BSE Sensex
| 13.08 | -1.05 | 2.13 | 24.69 | 11.60 | 16.47 | 11.89 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
|
|---|---|---|
|
Compass Therapeutics Inc (CMPX)
| -68.99 | 58.68 |
|
S&P Small-Cap 600
| 13.89 | -17.42 |
|
BSE Sensex
| 18.74 | 4.44 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$261.42 Mln
$3.69 Mln
$0.00 Mln
$146.23 Mln
$0.00 Mln
High
$0.77 - 2.34
137,588,992
NASDAQ: CMPX
Boston, MA
https://www.compasstherapeutics.com
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a... bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Address: 80 Guest Street, Boston, MA, United States, 02135 Read more
The total asset value of Compass Therapeutics Inc (CMPX) stood at $ 165 Mln as on 30-Jun-24
The share price of Compass Therapeutics Inc (CMPX) is $1.93 (NASDAQ) as of 04-Oct-2024 16:00 EDT. Compass Therapeutics Inc (CMPX) has given a return of -18.07% in the last 3 years.
Compass Therapeutics Inc (CMPX) has a market capitalisation of $ 261 Mln as on 02-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Compass Therapeutics Inc (CMPX) is 1.79 times as on 02-Oct-2024, a 43% discount to its peers’ median range of 3.12 times.
Since, TTM earnings of Compass Therapeutics Inc (CMPX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Compass Therapeutics Inc (CMPX) and enter the required number of quantities and click on buy to purchase the shares of Compass Therapeutics Inc (CMPX).
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Address: 80 Guest Street, Boston, MA, United States, 02135
The CEO & director of Dr. Vered Bisker-Leib M.D., MBA, Ph.D.. is Compass Therapeutics Inc (CMPX), and CFO & Sr. VP is Dr. Thomas J. Schuetz M.D., Ph.D..
There is no promoter pledging in Compass Therapeutics Inc (CMPX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Compass Therapeutics Inc. (CMPX) | Ratios |
|---|---|
|
Return on equity(%)
|
-32.07
|
|
Operating margin(%)
|
-1085.25
|
|
Net Margin(%)
|
-1278.88
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Compass Therapeutics Inc (CMPX) was $0 Mln.
$0.03
